Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

INTRODUCTION: Alport syndrome is a rare genetic disorder that affects as many as 60,000 persons in the USA and a total of 103,000 persons (<5 per 10,000) in the European Union [1, 2]. It is the second most common inherited cause of kidney failure and is characterized by progressive loss of kidney...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Nephrol
Asıl Yazarlar: Chertow, Glenn M., Appel, Gerald B., Andreoli, Sharon, Bangalore, Sripal, Block, Geoffrey A., Chapman, Arlene B., Chin, Melanie P., Gibson, Keisha L., Goldsberry, Angie, Iijima, Kazumoto, Inker, Lesley A., Knebelmann, Bertrand, Mariani, Laura H., Meyer, Colin J., Nozu, Kandai, O'Grady, Megan, Silva, Arnold L., Stenvinkel, Peter, Torra, Roser, Warady, Bradley A., Pergola, Pablo E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: S. Karger AG 2021
Konular:
Patient-Oriented, Translational Research: Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220919/
https://ncbi.nlm.nih.gov/pubmed/33789284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513777
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller